首页> 外文期刊>Journal of Translational Medicine >Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data
【24h】

Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data

机译:通过整合多组学数据识别用于个体化抗癌药物反应的子途径特征

获取原文
获取外文期刊封面目录资料

摘要

Individualized drug response prediction is vital for achieving personalized treatment of cancer and moving precision medicine forward. Large-scale multi-omics profiles provide unprecedented opportunities for precision cancer therapy. In this study, we propose a pipeline to identify subpathway signatures for anticancer drug response of individuals by integrating the comprehensive contributions of multiple genetic and epigenetic (gene expression, copy number variation and DNA methylation) alterations. Totally, 46 subpathway signatures associated with individual responses to different anticancer drugs were identified based on five cancer-drug response datasets. We have validated the reliability of subpathway signatures in two independent datasets. Furthermore, we also demonstrated these multi-omics subpathway signatures could significantly improve the performance of anticancer drug response prediction. In-depth analysis of these 46 subpathway signatures uncovered the essential roles of three omics types and the functional associations underlying different anticancer drug responses. Patient stratification based on subpathway signatures involved in anticancer drug response identified subtypes with different clinical outcomes, implying their potential roles as prognostic biomarkers. In addition, a landscape of subpathways associated with cellular responses to 191 anticancer drugs from CellMiner was provided and the mechanism similarity of drug action was accurately unclosed based on these subpathways. Finally, we constructed a user-friendly web interface-CancerDAP ( http://bio-bigdata.hrbmu.edu.cn/CancerDAP/ ) available to explore 2751 subpathways relevant with 191 anticancer drugs response. Taken together, our study identified and systematically characterized subpathway signatures for individualized anticancer drug response prediction, which may promote the precise treatment of cancer and the study for molecular mechanisms of drug actions.
机译:个性化药物反应预测对于实现癌症的个性化治疗和推动精密药物的发展至关重要。大规模的多组学谱为精确的癌症治疗提供了前所未有的机会。在这项研究中,我们提出了一条管道,通过整合多种遗传和表观遗传(基因表达,拷贝数变异和DNA甲基化)改变的综合作用,来确定个体抗癌药物反应的子途径签名。基于五个癌症药物反应数据集,共确定了46个与个体对不同抗癌药物反应相关的亚通路标志。我们已经在两个独立的数据集中验证了子路径签名的可靠性。此外,我们还证明了这些多组学子途径签名可以显着提高抗癌药物反应预测的性能。深入分析这46个子通路特征,揭示了三种组学类型的基本作用以及不同抗癌药物反应的潜在功能关联。基于参与抗癌药物反应的子途径特征的患者分层,可确定具有不同临床结局的亚型,这暗示了其作为预后生物标志物的潜在作用。另外,提供了与细胞对来自CellMiner的191种抗癌药的细胞应答相关的子途径的概况,并基于这些子途径准确地揭示了药物作用的机制相似性。最后,我们构建了一个用户友好的Web界面-CancerDAP(http://bio-bigdata.hrbmu.edu.cn/CancerDAP/),可用于探索与191种抗癌药物反应相关的2751条子途径。两者合计,我们的研究确定和系统地表征个性化抗癌药物反应预测的子途径签名,这可能会促进癌症的精确治疗和药物作用分子机制的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号